Loading clinical trials...
Loading clinical trials...
Phase I Open-label Dose Escalation Trial of BI 3923948 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced, Unresectable and/or Metastatic Solid Tumors
Conditions
Interventions
BI 3923948
Ezabenlimab
Locations
10
United States
Indiana University
Indianapolis, Indiana, United States
University of Minnesota
Minneapolis, Minnesota, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
CTR Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Start Date
April 2, 2026
Primary Completion Date
February 20, 2028
Completion Date
February 12, 2032
Last Updated
April 15, 2026
NCT07489378
NCT07181681
NCT07204340
NCT07360314
NCT07403721
NCT06721689
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions